Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.

Summary

Aim of this phase 2 study is to evaluate the safety and the efficacy of the combination of induction chemotherapy plus durvalumab followed by reduced-dose hypo-fractionated thoracic RT (concurrent with durvalumab) and durvalumab maintenance for stage 3 unresectable NSCLC patients candidate to sequential chemo-RT.

Timeline

Start

2021-10-28

Primary completion

2024-11-28

Completion

2025-11-28

Publications

• Agustoni F, Saddi J, Cortinovis DL, Arcangeli S, Sala L, Klersy C, Musella V, Galli G, Borgetto SMC, Stella GM, Cicognini D, Ferrari A, Pedrazzoli P, Grossi F, Filippi AR. Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial). JNCI Cancer Spectr. 2026 May 9;10(3):pkag050. doi: 10.1093/jncics/pkag050.

Drugs

Indications